Anzupgo Approved in Europe for Severe Hand Eczema
Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended the granting of marketing authorization for Anzupgo (delgocitinib; LEO Pharma) to treat moderate to severe chronic hand eczema in adults when topical corticosteroids are insufficient. A final decision from the European Commission is now pending. Chronic hand eczema is an inflammatory skin condition of the …
Read More
0
